- Home
- MYGN vs XRX Comparison
MYGN vs XRX Comparison
Compare MYGN & XRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- XRX
- Stock Information
- Founded
- MYGN 1991
- XRX 1906
- Country
- MYGN United States
- XRX United States
- Employees
- MYGN N/A
- XRX N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- XRX Computer peripheral equipment
- Sector
- MYGN Health Care
- XRX Technology
- Exchange
- MYGN Nasdaq
- XRX Nasdaq
- Market Cap
- MYGN 642.0M
- XRX 519.7M
- IPO Year
- MYGN 1995
- XRX N/A
- Fundamental
- Price
- MYGN $8.33
- XRX $3.61
- Analyst Decision
- MYGN Hold
- XRX Sell
- Analyst Count
- MYGN 13
- XRX 3
- Target Price
- MYGN $13.50
- XRX $6.83
- AVG Volume (30 Days)
- MYGN 959.5K
- XRX 4.0M
- Earning Date
- MYGN 11-04-2025
- XRX 10-30-2025
- Dividend Yield
- MYGN N/A
- XRX 2.79%
- EPS Growth
- MYGN N/A
- XRX N/A
- EPS
- MYGN N/A
- XRX N/A
- Revenue
- MYGN $832,900,000.00
- XRX $6,174,000,000.00
- Revenue This Year
- MYGN $0.06
- XRX $13.23
- Revenue Next Year
- MYGN $5.68
- XRX $8.32
- P/E Ratio
- MYGN N/A
- XRX N/A
- Revenue Growth
- MYGN 3.83
- XRX N/A
- 52 Week Low
- MYGN $3.76
- XRX $3.03
- 52 Week High
- MYGN $22.92
- XRX $10.48
- Technical
- Relative Strength Index (RSI)
- MYGN 64.16
- XRX 53.03
- Support Level
- MYGN $7.68
- XRX $3.03
- Resistance Level
- MYGN $8.25
- XRX $3.66
- Average True Range (ATR)
- MYGN 0.38
- XRX 0.16
- MACD
- MYGN -0.01
- XRX 0.05
- Stochastic Oscillator
- MYGN 78.80
- XRX 92.13
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About XRX Xerox Holdings Corporation
Xerox Holdings Corp is an original equipment manufacturing and software company. Xerox operates in one segment--design, development, and sale of printing technology and related solutions--while deriving 60% of its revenue from the U.S. and 40% from international markets. The company is an OEM of multifunction printers, or MFPs (printers that can print, copy, and scan), focusing on large enterprise markets. Apart from equipment, the company provides post-sales services like managed print services help to bring smart servicing and efficiencies to how employers use their print/copy equipment. Xerox is attempting to enter new markets like digital print packaging solutions and printed electronics.